Passage Bio Inc (NAS:PASG)
$ 0.7925 -0.0075 (-0.94%) Market Cap: 49.41 Mil Enterprise Value: -11.14 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Passage Bio Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 09:10PM GMT
Release Date Price: $20.64 (-0.63%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

My name is Gena Wang. I'm Senior Care Biotech Analysts at the Barclays. Welcome to our Second Virtual Global Healthcare Conference. It's my great pleasure to introduce our next presenter, Jill Quigley, hope I pronounced your last name right, the Chief Operating Officer from Passage. Jill, I hand over to you to share the slides.

Jill M. Quigley
Passage Bio, Inc. - COO

Wonderful. Thank you, Gena, and thank you to Barclays for having us today. Give me one second, I will put this in the right mode. Here we go. Wonderful. Nice to see everyone. Thank you for coming to our presentation today. Here is our forward-looking statement. We'll be making forward-looking statements during the presentation, and you should refer to our SEC filings for more information about that.

At Passage Bio, we're focused on developing gene therapies for rare monogenic CNS diseases. And what we know is that there's about 7,000 rare diseases that have been identified already, and there's already about 800 of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot